Aubrey Capital Management Ltd Sells 6,600 Shares of Boston Scientific Co. (NYSE:BSX)

Aubrey Capital Management Ltd trimmed its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 13.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,000 shares of the medical equipment provider's stock after selling 6,600 shares during the quarter. Boston Scientific makes up about 1.8% of Aubrey Capital Management Ltd's portfolio, making the stock its 13th biggest holding. Aubrey Capital Management Ltd's holdings in Boston Scientific were worth $4,438,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of BSX. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Union Bancaire Privee UBP SA bought a new position in Boston Scientific in the fourth quarter valued at approximately $33,074,000. Kingsview Wealth Management LLC boosted its stake in shares of Boston Scientific by 9.9% during the 4th quarter. Kingsview Wealth Management LLC now owns 6,563 shares of the medical equipment provider's stock worth $586,000 after acquiring an additional 593 shares during the period. Empowered Funds LLC boosted its stake in shares of Boston Scientific by 13.7% during the 4th quarter. Empowered Funds LLC now owns 26,615 shares of the medical equipment provider's stock worth $2,377,000 after acquiring an additional 3,202 shares during the period. Finally, Entropy Technologies LP bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $214,000. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company's stock, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the sale, the chief executive officer now directly owns 1,535,706 shares of the company's stock, valued at $157,379,150.88. The trade was a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 411,970 shares of company stock worth $42,406,693. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 1.1%

NYSE:BSX traded up $1.04 on Friday, hitting $99.60. The stock had a trading volume of 10,330,779 shares, compared to its average volume of 6,574,434. The business's fifty day moving average is $101.03 and its 200 day moving average is $98.79. The company has a market cap of $147.35 billion, a PE ratio of 79.68, a P/E/G ratio of 2.79 and a beta of 0.68. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 52 week low of $71.88 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company's quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.56 earnings per share. On average, equities research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on BSX shares. Robert W. Baird boosted their price target on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. BTIG Research restated a "buy" rating and issued a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, April 23rd. Morgan Stanley boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Royal Bank of Canada lifted their price objective on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Finally, Evercore ISI lifted their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Twenty-one research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $116.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.